Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel Shortage Strategies: Clinical Trials Will Provide “Bolus” Of Patients

Executive Summary

Immunex' ongoing Enbrel clinical trials will help provide a "bolus" of patients for the rheumatoid arthritis agent once the company expands its commercial capacity for the biologic
Advertisement

Related Content

Amgen files Enbrel plant sBLA
Amgen files Enbrel plant sBLA
Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says
Enbrel Supply Interruption Will Be Resolved By June, Immunex Says
Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Medicare Self-Injectable Drug Coverage Rule Expected By Spring
Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List
Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List
Advertisement
UsernamePublicRestriction

Register

PS039735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel